St. Baldrick’s Foundation Announces 2026 Ambassadors
Los Angeles, California--(Newsfile Corp. - January 6, 2026) - The St. Baldrick's Foundation, the largest charity funder of childhood cancer...
Clinical Trial
How Does Community-Based Research Deliver Faster Results and Greater Access? Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insights into community-based research models and how they compare to traditional site-based models. Attendees will...
WCG Unveils 2026 Trends and Insights Report: Charting a New Era of Readiness, Innovation, and Human-Centric Clinical Research
CARY, N.C., Jan. 6, 2026 /PRNewswire/ -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical...
NanOlogy Appoints John M. Goldberg, MD as Chief Medical Officer to Further its Preclinical & Clinical Large Surface Area Microparticle Investigational Drug Portfolio
FORT WORTH, Texas, Jan. 6, 2026 /PRNewswire/ -- NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of John...
Behind the Relapse No One Saw Coming: How First Ascent Biomedical Is Changing Cancer Treatment Decisions
Logan Jenner, a five-year-old battling acute myeloid leukemia, found new hope through a clinical trial that used Functional Precision Medicine...
Article About Groundbreaking Results from Study of Jaguar Health’s Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in...
Stemtech Corporation Appoints Dr. Lizette Leos, MD To Chief Scientific Officer (CSO)
NAPLES, FL / ACCESS Newswire / January 6, 2026 / Stemtech Corporation, the global leader and pioneer in stem cell...
Mmimetika Appoints Metabolic Health Expert Karan Sarin as CEO to Lead Global Commercialization
AARHUS | Author of "Sick Nation" and veteran startup operator joins as company advances lactate-ketone ester through regulatory approval with...
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in...
Cumulus Neuroscience Publishes Data Validating a Scalable Measurement of Neuroplasticity Using Low-Burden Dry Sensor EEG
Data published in Scientific Reports confirms a low-burden visual evoked potential (VEP) assessment can be employed across multiple clinical trial sites as an...
Xironetic Appoints Brandon Strong as Chief Product Officer and Chief Research Officer
SACRAMENTO, CALIFORNIA / ACCESS Newswire / January 5, 2026 / Xironetic, a provider of augmented reality surgical guidance technology, today...
Adia Nutrition Inc. Announces Landmark Autism Spectrum Disorder Clinical Study Now Live on ClinicalTrials.gov
Winter Park, Florida--(Newsfile Corp. - January 5, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine...
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted...
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology...
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and...
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company...
Medera Announces Completion of Patient Enrollment in Cohort B of MUSIC-HFpEF Phase 1/2a Clinical Trial
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by...
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
FSdC demonstrated statistically significant and superior improvement in disc preservation and structural integrity compared to other treatmentsHOUSTON, Jan. 05, 2026...
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms...
SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a Disease-modifying Therapy for Parkinson’s Disease
SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to...